
Lonza collaborates with Asher Biotherapeutics Inc
Asher Biotherapeutics is a developer of targeted immunotherapies for cancer, chronic viral infections and autoimmune disorders. AB248, Asher Bio’s...

Pfizer-Seagen: Acquisition in the works
As announced earlier this week, Pfizer Inc. plans to purchase Seagen for US$43bn. The Boards of Directors of both companies approved the transaction...

Abivax SA raises €130m to advance obefazimod to Phase III
Existing investors Invus, Deep Track Capital, Sofinnova Partners, Venrock Healthcare Capital Partners, as well as from new investors Great Point...

First allogeneic cancer immunotherapy hits market
On December 20th, the European Commission approved Tabelecleucel (EbvalloTM) as a monotherapy for the treatment of adult and paediatric patients who...

New polymer can stop biofilm formation
The acrylate co-polymer reported by Jean-Frédéric Dubern and colleagues in Science Advances (doi: 10.1126/sciadv.add7474) have the potential to...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

Ethris inks €15m deal with Indian Ciplas
The investment is aimed at establishing a long-term strategic partnership until the end of Q1/2023 between Cipla and Ethris for the development of...